Vaccine R&D Tax Credit Proposal Supported By Findings In CRS Report

A 30% tax credit on vaccine R&D could be as cost- effective as direct federal investment in vaccine development through government grants, a Congressional Research Service report states.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet